Drugs / Spironolactone
Spironolactone
also known as
Aldactone · SPL · Abbolactone · Carospir · Diatensec · Espironolactona · Gx spironol · Laractone · +18 more
Small molecule targets NR3C2, RXRG via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Qaialdo | — | 2023-05-26 | europa.eu ↗ |
| Label expansion | US (FDA) | ALDACTONE | — | 1981-06-30 | fda.gov ↗ |
| Approved | US (FDA) | ALDACTONE | — | 1960-01-21 | fda.gov ↗ |
Trials 151 · started per year
today
US approved 1960
EU approved 2023
1
1
1
2
4
4
7
5
5
5
2
9
6
3
8
7
8
5
3
7
7
7
7
12
7
8
3
6
19591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
Also used as a comparator or background therapy in 102 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02689843 Comparator | Feb → Nov 2018 | polycystic ovary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03068910 Comparator | Jul 2016 → Oct 2025 overdue | polycystic ovary syndrome | University of Virginia | Recruiting | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06205407 Comparator | Dec 2023 → Mar 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03682497 Comparator | Nov 2018 → Mar 2020 | heart failure | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT02941315 Comparator | Dec 2016 → Oct 2021 | idiopathic cardiomyopathy | RenJi Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01821703 Comparator | May → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01488877 Comparator | Jan → Jul 2012 | diabetic kidney disease | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01103245 Comparator | Mar 2010 → Jul 2012 | diabetes mellitus | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00857909 Comparator | Jan 2009 → Jul 2010 | hypertensive disorder | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07431216 Background | May 2026 → May 2027 expected | glioblastoma | Starlight Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03867682 Background | Jan 2020 → Nov 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02575963 Background | Oct 2012 → Nov 2018 | acute myeloid leukemia | Actinium Pharmaceuticals | Completed | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT07539259 Comparator | Dec 2026 → Aug 2029 expected | aortic valve stenosis | University College, London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07304817 Comparator | May 2026 → Feb 2028 expected | chronic kidney disease, heart failure | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT05010707 Comparator | Aug 2021 → Aug 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04785755 Background | Nov 2017 → Mar 2020 | — | Hala Abd EL-Tawab Ibrahim Radwan | Completed | No outcome recorded |
| Phase 2 | NCT03329443 Comparator | Sep 2017 → Sep 2018 | acute kidney injury, myocardial ischemia | Alhasan Mujtaba Abdul-Wahid | Completed | No outcome recorded |
| Phase 2 | NCT03071263 Background | Jan 2017 → Nov 2018 | resistant hypertension | Relypsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02501213 Comparator | May 2016 → Nov 2017 | cancer | Centre Oscar Lambret | Terminated | No outcome recorded |
| Phase 2 | NCT02235077 Comparator | Dec 2014 → Apr 2016 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT02285920 Comparator | Nov 2014 → Jun 2017 | end stage renal failure | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02230891 Comparator | Oct 2014 → Dec 2020 | diabetes mellitus, hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT02236520 Comparator | Sep 2014 → May 2018 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT02194465 Comparator | Aug 2014 → Mar 2015 | essential hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01691053 Comparator | Dec 2012 → Feb 2017 | end stage renal failure | Wuerzburg University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01371747 Background | Jun 2011 → May 2013 | chronic kidney disease, hypertensive disorder | Relypsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01345656 Comparator | May 2011 → May 2012 | heart failure | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01130597 Background | May → Sep 2010 | heart failure | Relypsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01021943 Comparator | Nov 2009 → ? | — | Instituto Nacional de Cardiologia Ignacio Chavez | Suspended | No outcome recorded |
| Phase 2 | NCT00291720 Comparator | Apr 2005 → Dec 2007 | cardiovascular disorder, chronic kidney disease | University Hospital Birmingham | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02040441 Comparator | Mar 2014 → Nov 2018 | diabetic kidney disease, diabetic retinopathy | Peter Rossing | Completed | No outcome recorded |
| Phase 2/3 | NCT02173288 Background | Jul 2013 → Mar 2016 | cirrhosis of liver | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT01721655 Comparator | Oct 2012 → Dec 2016 | bronchopulmonary dysplasia | West Virginia University Healthcare | Unknown | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT07223502 Comparator | Dec 2025 → Jul 2026 overdue | hypertensive disorder | Sarfez Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05849766 Comparator | Apr 2023 → May 2024 | dilated cardiomyopathy | October 6 University | Completed | No outcome recorded |
| Phase 3 | NCT03653845 Background | Jul 2018 → Jul 2019 | hypertensive disorder, primary aldosteronism | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03048825 Comparator | Feb 2018 → Aug 2024 | ST-elevation myocardial infarction | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02901184 Comparator | Nov 2017 → Dec 2026 expected | diastolic heart failure | Uppsala University | Recruiting | No outcome recorded |
| Phase 3 | NCT03020303 Comparator | Jul 2017 → Mar 2025 | end stage renal failure | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02354352 Comparator | Mar 2015 → May 2018 | Duchenne muscular dystrophy | Ohio State University | Completed | No outcome recorded |
| Phase 3 | NCT02764619 Comparator | Dec 2013 → Feb 2017 | atrial fibrillation | Svendborg Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01882179 Comparator | Nov 2013 → May 2016 | ST-elevation myocardial infarction | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT01848639 Comparator | Jun 2013 → Nov 2022 | end stage renal failure | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT01586442 Comparator | Mar 2012 → Mar 2015 | glucose intolerance, heart failure, type 2 diabetes mellitus | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 3 | NCT00865449 Comparator | Jul 2008 → Dec 2011 | end stage renal failure | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| Phase 433 trials | ||||||
| Phase 4 | NCT07523867 Comparator | Apr → Oct 2026 expected | diabetic kidney disease, heart failure | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07281014 Comparator | Jan 2026 → Aug 2027 expected | heart failure | Yale University | Recruiting | No outcome recorded |
| Phase 4 | NCT06457074 Comparator | Jun 2024 → Jun 2025 overdue | primary aldosteronism | Qifu Li | Recruiting | No outcome recorded |
| Phase 4 | NCT06164379 Comparator | Dec 2023 → Dec 2024 | primary aldosteronism | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT05814770 Comparator | May 2023 → Mar 2025 | hypertensive disorder, primary aldosteronism | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT04331691 Comparator | Nov 2020 → May 2024 | resistant hypertension | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT03984591 Comparator | Nov 2020 → Dec 2028 expected | systolic heart failure | Bispebjerg Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04618601 Comparator | Oct 2020 → Dec 2021 | heart failure | Laiko General Hospital, Athens | Unknown | No outcome recorded |
| Phase 4 | NCT04100083 Comparator | Sep 2020 → Jun 2021 | hidradenitis suppurativa | Medical University of South Carolina | Withdrawn | No outcome recorded |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04062760 Background | Dec 2019 → Dec 2021 | heart failure | University of Parma | Unknown | No outcome recorded |
| Phase 4 | NCT03502031 Comparator | Oct 2018 → Oct 2022 | diabetic kidney disease | James A. Tumlin, MD | Unknown | No outcome recorded |
| Phase 4 | NCT02907749 Comparator | Jan 2018 → Jan 2020 | cirrhosis of liver, portal hypertension | Changqing Yang | Completed | No outcome recorded |
| Phase 4 | NCT02483195 Comparator | Aug 2016 → Aug 2018 | androgenetic alopecia | University of Florida | Withdrawn | No outcome recorded |
| Phase 4 | NCT02253394 Comparator | Sep 2015 → Feb 2018 | pulmonary arterial hypertension | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT02046668 Comparator | Nov 2013 → Mar 2015 | osteoarthritis, knee | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT01945801 Comparator | Oct 2013 → Feb 2015 | obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT03429946 Comparator | Jul 2013 → Nov 2025 | hypoglycemia | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT01643434 Comparator | Aug 2012 → Dec 2013 | hypertensive disorder | Instituto do Coracao | Unknown | No outcome recorded |
| Phase 4 | NCT01510795 Comparator | Jan 2012 → Jun 2013 | chronic renal failure syndrome | Clinical Hospital Merkur | Unknown | No outcome recorded |
| Phase 4 | NCT02053974 Comparator | Sep 2011 → Oct 2012 | cardiomyopathy due to anthracyclines | TC Erciyes University | Completed | No outcome recorded |
| Phase 4 | NCT01388088 Comparator | Sep 2010 → Feb 2012 | hypertensive disorder | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 4 | NCT01271374 Comparator | Apr 2010 → Jun 2011 | hypertensive disorder | InVasc Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT02369081 Comparator | May 2009 → Jul 2015 | resistant hypertension | University of Cambridge | Unknown | No outcome recorded |
| Phase 4 | NCT00524615 Comparator | Sep 2007 → Oct 2012 | hypertensive disorder | Jan Vaclavík | Unknown | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00332904 Comparator | Aug 2006 → Jul 2008 | cirrhosis of liver, portal hypertension | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00353652 Comparator | Jan 2005 → Jan 2013 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04495712 Comparator | Jul 2004 → May 2008 | cardiac rhythm disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT00206232 Comparator | Jul 2004 → Jul 2010 | heart failure | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00226109 Comparator | Apr 2004 → Aug 2011 | alcohol dependence, alcoholic cardiomyopathy | University of Aarhus | Suspended | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07331220 Background | Dec 2026 → Dec 2028 expected | diastolic heart failure | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07585526 Comparator | Apr 2026 → Mar 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT07130175 Background | Dec 2022 → Dec 2024 | heart failure, polymorphic ventricular tachycardia | Qian Feng | Completed | No outcome recorded |
| — | NCT05501080 Comparator | Sep 2022 → Sep 2025 overdue | primary aldosteronism | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT07328230 Comparator | Aug 2022 → Dec 2025 overdue | hyperaldosteronism | Chinese Academy of Medical Sciences, Fuwai Hospital | Recruiting | No outcome recorded |
| — | NCT05287100 Background | Jan 2022 → May 2023 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT04367051 Comparator | Aug 2020 → Dec 2021 | heart failure | Asan Medical Center | Completed | No outcome recorded |
| — | NCT03645642 Background | Sep → Dec 2018 | hepatobiliary disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT03547895 Comparator | Jun 2015 → May 2016 | cirrhosis of liver | Zagazig University | Completed | No outcome recorded |
| — | NCT02364089 Comparator | Apr 2015 → Mar 2022 | adrenal gland disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01953874 Background | Dec 2013 → Dec 2015 | heart failure, sleep apnea syndrome | ResMed | Terminated | No outcome recorded |
| — | NCT01817803 Comparator | Mar 2013 → Jun 2015 | congestive heart failure | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT02039492 Comparator | Sep 2012 → Dec 2015 | resistant hypertension | Parc de Salut Mar | Completed | No outcome recorded |
| — | NCT02167464 Comparator | Jun 2011 → Jan 2015 | hypertensive disorder | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT01195805 Comparator | Aug 2010 → Aug 2015 | essential hypertension | Regional Hospital Holstebro | Completed | No outcome recorded |
| — | NCT01526616 Comparator | May 2010 → May 2011 | polycystic ovary syndrome | University Magna Graecia | Completed | No outcome recorded |
| — | NCT01406015 Comparator | Feb 2009 → Aug 2013 | obesity disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT01897727 Comparator | Jan 2009 → Apr 2012 | hyperaldosteronism, obstructive sleep apnea syndrome, resistant hypertension | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00709137 Comparator | Oct 2008 → Oct 2010 | hypertensive disorder | VA Salt Lake City Health Care System | Withdrawn | No outcome recorded |
| — | NCT00773084 Comparator | Sep 2008 → Aug 2009 | diastolic heart failure | Texas Tech University Health Sciences Center | Withdrawn | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00224809 Background | Sep 2002 → May 2007 | coronary artery disorder | Baylor Research Institute | Completed | No outcome recorded |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 256 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spironolactone | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗251“Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily)....” NCT07130175 ↗ “One group was treated with mineralocorticoid receptor antagonists(MRAs) (including spironolactone 20-60mg/ day, or eplerenone50-100mg/day, or finerenone 10-20mg/ day) in...” NCT05688579 ↗ “1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible” NCT01882179 ↗ “Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.” NCT04062760 ↗ “The investigators hypothesize that the mineralocorticoid receptor antagonist (MRA), spironolactone, may prevent HF by acting on extracellular matrix remodelling” NCT02556450 ↗ “Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated” NCT01953874 ↗ “Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable).” NCT04142788 ↗ “Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio)” NCT04785755 ↗ “Antiandrogen therapy with spironolactone started at a dose of 50 mg daily and increased every 4 weeks to 200 mg daily” NCT03757117 ↗ “All patients will be randomized to receive spironolactone 25 mg per day or not for at least 6 months.” NCT01944384 ↗ “Patients will be randomized (1:1) to renal sympathetic denervation treatment or spironolactone (50mg)” NCT02039492 ↗ “amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d” NCT03653845 ↗ “A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic” NCT05287100 ↗ “MRA (Spironolactone, Eplerenone) will be introduced and up titrated in week 3 and 7 respectively.” NCT05637853 ↗ “Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.” NCT02173288 ↗ “Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.” NCT04633005 ↗ “GDMT regimen including sodium-glucose co-transporter 2 inhibitor (SGLT2i) + spironolactone.” NCT07331220 ↗ “MRA: spironolactone or eplerenone (at the maximally tolerated dose, according to the SmPC)” NCT07513883 ↗ “aldosterone antagonists, both non-selective (spironolactone) and selective (eplerenone)” PMID 33586138 ↗ Feb 2021 “Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin” NCT06091475 ↗ “Mineralocorticoid receptor antagonist, including spironolactone or eplerenone” NCT04575675 ↗ “first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop” NCT02200822 ↗ “triamterene, eplerenone, spironolactone, atenolol, betaxolol” NCT00684489 ↗ “combined spironolactone 100 mg plus furosemide 20 mg daily” PMID 25906818 ↗ Apr 2015 “representative drugs spironolactone and eplerenone” NCT07335900 ↗ “spironolactone 25 mg once daily added to losartan” NCT01667614 ↗ “* step 5: Add-on of Spironolactone 25 mg” NCT02364089 ↗ “captopril, fursemide, spironolactone” NCT02941315 ↗ “Spironolactone 12.5 - 25mg daily” NCT02167464 ↗ “spironolactone 12.5 to 25 mg/d” NCT02539810 ↗ “spironolactone 25 once daily” NCT01271374 ↗ “3. Spironolactone 20mg qd” NCT04980716 ↗ |
| Known as | Abbolactone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Aldactone | “Spironolactone (Aldactone) is an antiandrogen that also reduced testosterone synthesis by inhibiting the enzyme 17-hydroxylase.” NCT00001202 ↗4“Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.” NCT03645642 ↗ “100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.” NCT00860340 ↗ “Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®” NCT05849766 ↗ “Aldactone” NCT02417896 ↗ |
| Known as | Carospir | “Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL)” NCT03909529 ↗ |
| Known as | Diatensec | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Espironolactona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Gx spironol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Laractone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | NSC-150399 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Qaialdo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | SC-9420 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiro | “before and after spironolactone (Spiro).” PMID 20550533 ↗ Nov 2010 |
| Known as | Spiroctan 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiroctan 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spiroctan 50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironol | “Spironolactone (Spironol) 25 mg” NCT00528385 ↗ |
| Known as | Spironolactone ARROW | “Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial” NCT03334682 ↗ |
| Known as | Spironolactone ceva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironolactone component of aldactazide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironolactone component of cardalis | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spironolactonum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spirospare 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | Spirospare 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Known as | SPL | “The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.” NCT02285920 ↗1“Spironolactone (SPL), a mineralocorticoid receptor antagonist” NCT05222191 ↗ |
| Known as | Verospiron | “Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ |
| Known as | Verospirone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1393 ↗ |
| Action | Inhibit | “spironolactone to inhibit the action of androgen” NCT00001202 ↗1“Mineralocorticoid receptor antagonist” CHEMBL1393 ↗ |
| Modality | Small molecule | “the steroidal mineralocorticoid receptor antagonist spironolactone” PMID 40818851 ↗ Aug 2025 |
| Route | Oral | “oral spironolactone” NCT00004311 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL1393 ↗ |
| Target | RXRG | “retinoid X receptor gamma (RXRg) agonist spironolactone” NCT05754684 ↗ |